SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis.

Deepson S ShyangdanOlalekan A UthmanNorman Waugh

Published in: BMJ open (2016)

There were few differences among the SGLT-2 inhibitors, but in monotherapy, the glucose-lowering effect of canagliflozin 300 mg is slightly greater than most other SGLT-2 inhibitors.

Keyphrases

randomized controlled trial
clinical trial
type diabetes
metabolic syndrome
adipose tissue